Literature DB >> 30980944

Mutation spectrum and pivotal features for differential diagnosis of Mucopolysaccharidosis IVA patients with severe and attenuated phenotype.

Beyhan Tüysüz1, Dilek Uludağ Alkaya2, Güven Toksoy3, Nilay Güneş2, Timur Yıldırım4, İlhan Avni Bayhan4, Zehra Oya Uyguner3.   

Abstract

Mucopolysaccharidosis IVA (MPS IVA) is a lysosomal storage disease caused by biallelic mutations in GALNS gene and characterized by progressive skeletal deformities with short stature. The aim of this study was to evaluate the genotype, longitudinal height measurement and clinical features of MPS IVA patients. Thirty-two patients from 22 families were enrolled. The ages of patients at diagnosis ranged from two months to 18 years of age, and followed up for three to twenty years. They were classified as severe and attenuated form (intermediate and mild) according to their height measurements. The mean height standard deviation scores (SDS) for Turkish standards at 0-3, 5 and 10 years of ages were found to be -1.1, -4.2 and -7.3 respectively in patients with severe phenotype, while they were +0.4, -1.5 and -3 for intermediate phenotype. Patients with severe form reached a mean final height of -8.5 SDS, and mild phenotype -3.6 SDS. The most common initial and current symptoms in the patients with the severe phenotype were pectus carinatus and/or kyphosis deformities which occurred between 5 months and 3 years of age, and genu valgum deformity which developed after 3 years of age. However, kyphoscoliosis was the most common initial and current findings in the attenuated phenotype. Although, initial symptoms appeared in early childhood in the intermediate phenotype, similar to the severe phenotype, the clinical findings progressed slowly and genu valgum deformity did not develop. In patients with mild phenotype, the onset of symptoms was after 5 years of age. In conclusion, this study provides significant insights into the initial and follow-up clinical features and height values that contribute to the differential diagnosis of the severe and intermediate phenotypes in early childhood. Eleven mutations in GALNS gene in which one of them is novel (c.416G>A) were associated with the severe phenotype and three mutations (c.1038C>A, c.850T>G, c.752G>A) lead to the attenuated phenotype.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Attenuated form; GALNS gene; Height; MPS-IVA; Phenotype

Mesh:

Substances:

Year:  2019        PMID: 30980944     DOI: 10.1016/j.gene.2019.04.026

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  5 in total

1.  The GALNS p.P77R variant is a probable Gujarati-Indian founder mutation causing Mucopolysaccharidosis IVA syndrome.

Authors:  Harsh Sheth; Premal Naik; Maulin Shah; Riddhi Bhavsar; Aadhira Nair; Frenny Sheth; Jayesh Sheth
Journal:  BMC Genomics       Date:  2022-06-21       Impact factor: 4.547

2.  Case Report: Diagnosis of Mucopolysaccharidosis Type IVA With Compound Heterozygous Galactosamine-6 Sulfatase Variants and Biopsy of Replaced Femoral Heads.

Authors:  Yiyang Ma; Hao Peng; Fuchou Hsiang; Haoyu Fang; Dajiang Du; Chenyi Jiang; Yehui Wang; Chun Chen; Changqing Zhang; Yun Gao
Journal:  Front Pediatr       Date:  2022-07-04       Impact factor: 3.569

3.  Separating gene clustering in the rare mucopolysaccharidosis disease.

Authors:  Leon Bobrowski; Tomasz Łukaszuk; Lidia Gaffke; Zuzanna Cyske; Mariusz Ferenc; Karolina Pierzynowska; Grzegorz Węgrzyn
Journal:  J Appl Genet       Date:  2022-03-24       Impact factor: 3.240

Review 4.  Molecular basis of mucopolysaccharidosis IVA (Morquio A syndrome): A review and classification of GALNS gene variants and reporting of 68 novel variants.

Authors:  Alessandra Zanetti; Francesca D'Avanzo; Moeenaldeen AlSayed; Ana Carolina Brusius-Facchin; Yin-Hsiu Chien; Roberto Giugliani; Emanuela Izzo; David C Kasper; Hsiang-Yu Lin; Shuan-Pei Lin; Laura Pollard; Akashdeep Singh; Rodolfo Tonin; Tim Wood; Amelia Morrone; Rosella Tomanin
Journal:  Hum Mutat       Date:  2021-08-23       Impact factor: 4.700

5.  Activity of daily living in mucopolysaccharidosis IVA patients: Evaluation of therapeutic efficacy.

Authors:  Hui Chen; Shaukat Khan; Betul Celik; Yasuyuki Suzuki; Yasuhiko Ago; Shunji Tomatsu
Journal:  Mol Genet Genomic Med       Date:  2021-10-08       Impact factor: 2.183

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.